EllisLab_ rockstar post doc, Beatriz, presents her work on comparing the chromatin landscape in racially diverse #prostatecancer patients Society for Basic Urologic Research | SBUR poster session #SBUR2024 #nextgen #chromatin

Back in Boston. Happy to be able to talk all things BRCA at the Center for BRCA & Related Genes Annual Scientific Symposium Dana-Farber #BRCA #itsinthegenes

I love when audience members nod and smile at me when I give a talk. I see you! #womeninmedicine #WomenInSTEM

Since #EMBARK data there is a need to define high risk #BCR #ProstateCancer Best data I have seen comes from Johns Hopkins Medicine team Risk of mets at 5 years is only 26% for #PSA DT 6-9 months. Significantly lower risk than DT 3-6 mos or DT under 3 mos ascopubs.org/doi/10.1200/JC…

Your natural history study with PSMA PET imaging will be incredibly important. We did not find an association between PSADT and a positive PSMA PET. To me this suggests that novel imaging may not inform who needs treatment. PSADT still the gold standard.

My cancer research career began 13 years ago in the Druker lab, where I learned to believe I could be a physician-scientist. This is a huge loss for Oregon, and likely a reflection of the current state of academic medicine

Calling GU junior faculty & fellows! 📣 Apply for the 2025 GU Early Career Thought Leaders conference in Philadelphia 3/6-3/8, led by me & Zach Klaassen. Secure your spot for 2 days of professional development & networking: forms.gle/jMG7iKfAYomuad… OncoAlert YUO #SUO24

Hola Bogota! Excited to be apart of the #PCF Visiting Professorship to exchange ideas to improve patient health Prostate Cancer Foundation PCF Science

Welcoming Dr. Helen Moon Helen Moon to the platform #ProstateCancer #bladdercancer #RCC #GUoncology #MedTwitter Rick Lee 이재방 Edwin Posadas, MD Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)

🎉Our @NCICCR_MIP Team had a very successful #RSNA2024 meeting 💪We will work harder to represent our #TeamScience in #RSNA2025 🙏Grateful to our collaborators, colleagues, patients, and their families for their trust in our science #CancerResearch #ArtificialIntelligence #AI

Bridging evidence to practice: #BladderCancer therapy guidelines and global implementation. Andrea Apolo, M.D. National Cancer Institute and Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center discuss new standards in bladder cancer care, spotlighting the #EV302 and #CheckMate901 trials. Enfortumab vedotin + pembro now sets

Fantastic to see this out. Congratulations Lisa Chesner, PhD Amy Moran Lab Felix Feng and the awesome team 👇

#PSMA imaging is showing #ProstateCancer in a WAY never seen before but it is unlikely to be showing Prostate Cancer that we have never encountered before The presumption of the latter leads to aggressive therapy which may not be required More data on this coming from National Cancer Institute

PSMA PET in #ProstateCancer: Balancing Sensitivity and Clinical Relevance. Ravi A Madan M.D. National Cancer Institute joins Oliver Sartor, MD Mayo Clinic to discuss the implications of using PSMA PET scans in #mCRPC. #Watch the full interview on UroToday > bit.ly/4fxWbx3

📣I am happy to share our new publication "A Prostate Imaging-Reporting and Data System version 2.1-based predictive model for clinically significant prostate cancer diagnosis" 🏅Congratulations to David Gelikman, MD who led this important collaboration with UAB Team Soroush Rais-Bahrami, MD, MBA, FACS

Happy holidays from the NCI #BladderCancer Research Team! NCI CCR GU Malignancies @NCICCR_MOS @NCICCR_UroOnc National Cancer Institute

A special thank you and holiday wishes to all patients (& their families) out there who took part in clinical trials. For them the giving spirit is never limited to a single time of year Thank you all!

In Memory of Dr Felix Feng, our beloved friend and a giant in prostate cancer by Misha Beltran in European Urology sciencedirect.com/science/articl… cc: Nancy Lin, MD Mary Feng UCSF Helen Diller Family Comprehensive Cancer Ctr Paul Nguyen Josh Lang Karen Knudsen, MBA PhD Prostate Cancer Foundation

Congratulations Dr. Apolo Andrea Apolo, M.D. NCI CCR GU Malignancies